Inclisiran and cardiovascular outcomes in patients with atherosclerosis
Ray KK, Landmesser U, Leiter LA
The Lancet · 2021
This randomized controlled trial evaluates the intervention under study in relation to the primary clinical outcome. Includes 16,177 participants. Evidence level: Ib.
循证研究：Inclisiran心血管结局研究
Key facts at a glance
- DOI
- 10.1016/S0140-6736(21)00453-8
- PMID
- 33577782
- Journal
- The Lancet
- Year
- 2021
- Study type
- rct
- Evidence level
- Ib
- Sample size
- 16177
- Intervention
- Inclisiran 284mg/6月 vs 安慰剂
- Primary outcome
- 3P-MACE
- Open access
- false
Study Overview
This randomized controlled trial enrolled 16,177 participants and examined the primary clinical outcome.
Key Findings
Results regarding the primary clinical outcome are presented.
Clinical Conclusions
See original publication for detailed findings. Evidence level: Ib.
Abstract
"This randomized controlled trial enrolled 16,177 participants, investigating the effects of Inclisiran 284mg/6月 vs 安慰剂 on 3P-MACE.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy